[Federal Register Volume 84, Number 35 (Thursday, February 21, 2019)]
[Notices]
[Page 5501]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-02881]
[[Page 5501]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Research
Triangle Institute
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before March 25, 2019. Such
persons may also file a written request for a hearing on the
application on or before March 25, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on June
25, 2018, Research Triangle Institute, 3040 East Cornwallis Road,
Hermann Bldg., Room 106, Research Triangle Park, North Carolina 27709,
re-applied to be registered as a bulk manufacturer of small quantities
of Tetrahydrocannabinols (7370), a basic class of a controlled
substance listed in schedule I.
The company will manufacture via synthesis Tetrahydrocannabinols
(7370), for use by researchers as Active Pharmaceutical Ingredients
(API) for clinical trials.
Dated: January 29, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-02881 Filed 2-20-19; 8:45 am]
BILLING CODE 4410-09-P